Our Solutions

Gain strategic, in-depth insights across your product’s lifecycle.

MMS is the trusted, data-focused clinical research organization (CRO) chosen by Sponsors across the globe for our dedication to providing comprehensive, integrated solutions in all aspects of drug development. Our expertise spans regulatory submissions support from pre-IND to marketing authorization, comprehensive safety solutions, full-service biometrics management and execution, and functional service provider (FSP) models, with a deep bench of therapeutic area expertise.

We believe in delivering strategic, in-depth insights which focus on the long-term success of our customers and their assets. This holistic approach ensures that every aspect of your drug development process is meticulously managed, from initial IND submissions through to marketing authorization approvals and post-approval activities. What sets MMS apart is our unwavering focus on data-driven methodologies and a commitment to delivering tailored, end-to-end solutions that are necessary to drive your programs and projects to success. The result is successful outcomes for our customers and the best customer satisfaction and employee stability in the industry.

Explore our solutions to see how MMS can help you achieve your drug development goals with confidence and precision.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer